First, the combination of CK2 inhibitors with other drugs might not be convenient: in melanoma and thyroid carcinoma with wt BRAF, the effect of CK2 inhibition in combination with vemurafenib or selumetinib (BRAF/MEK inhibitors) was poor or even antagonistic [89]. Here, BRAF is linked to thyroid gland carcinoma.